Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study

Affiliations

¹ Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy.
² Department of Medical Biotechnology, University of Siena, Siena, Italy.
³ Department of Dermatology, University of Pisa, Pisa, Italy.
⁴ Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
⁵ Unit of Dermatology, San Donato Hospital, Arezzo, Italy.
⁶ Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy.
⁷ Department of Dermatology, San Jacopo Hospital, Pistoia, Italy.
⁸ Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy.
⁹ Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy.

Martina Dragotto et al. J Eur Acad Dermatol Venereol. 2023.

. 2023 Apr 16.

doi: 10.1111/jdv.19117. Online ahead of print.

¹ Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy.
² Department of Medical Biotechnology, University of Siena, Siena, Italy.
³ Department of Dermatology, University of Pisa, Pisa, Italy.
⁴ Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
⁵ Unit of Dermatology, San Donato Hospital, Arezzo, Italy.
⁶ Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy.
⁷ Department of Dermatology, San Jacopo Hospital, Pistoia, Italy.
⁸ Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy.
⁹ Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy.

No abstract available

References

1. Trovato E, Rubegni P, Cinotti E. The immunogenetics of psoriasis. Adv Exp Med Biol. 2022;1367:105-17.
1. Prignano F, Pescitelli L, Trovato E, Di Cesare A, Cuccia A, Mazzatenta C, et al. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. Ital J Dermatol Venerol. 2022;157:469-79.
1. Trovato E, Rubegni P, Prignano F. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opin Biol Ther. 2022;22(12):1443-8.
1. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-8.
1. Krueger JG, Ferris LS, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A MAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116-124.e7.